Ser488

Site Information
LSASPRMsGFIyQGk SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 452424

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 5 ) , mass spectrometry ( 1 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ) , mutation of modification site ( 5 ) , western blotting ( 5 )
Disease tissue studied:	breast cancer ( 7 , 18 , 19 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , cervical cancer ( 43 ) , cervical adenocarcinoma ( 43 ) , leukemia ( 20 , 26 , 28 , 53 ) , acute myelogenous leukemia ( 20 , 26 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 17 , 20 ) , acute megakaryoblastic leukemia (M7) ( 17 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 17 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 17 ) , acute myeloblastic leukemia, without maturation (M1) ( 17 ) , chronic myelogenous leukemia ( 53 ) , T cell leukemia ( 28 ) , hepatocellular carcinoma, surrounding tissue ( 40 ) , lung cancer ( 6 , 12 , 19 , 31 , 36 ) , non-small cell lung cancer ( 19 ) , non-small cell lung adenocarcinoma ( 6 , 12 , 31 ) , lymphoma ( 8 ) , B cell lymphoma ( 17 ) , Burkitt's lymphoma ( 8 ) , non-Hodgkin's lymphoma ( 17 ) , follicular lymphoma ( 8 ) , mantle cell lymphoma ( 8 ) , pancreatic ductal adenocarcinoma ( 11 ) , multiple myeloma ( 17 ) , prostate cancer ( 42 ) , melanoma skin cancer ( 4 ) , FTLD ( 34 )
Relevant cell line - cell type - tissue:	'brain, cerebral cortex' ( 34 ) , 'muscle, skeletal' ( 27 ) , 'pancreatic, ductal'-pancreas ( 11 ) , 'stem, embryonic' ( 46 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 38 ) , 293E (epithelial) ( 30 ) , 786-O (renal) [VHL (human), transfection] ( 3 ) , 786-O (renal) ( 3 ) , A498 (renal) ( 39 ) , A549 (pulmonary) ( 13 ) , AML-193 (monocyte) ( 17 , 20 ) , BJAB (B lymphocyte) ( 8 ) , breast ( 1 ) , BT-20 (breast cell) ( 19 ) , BT-549 (breast cell) ( 19 ) , Calu 6 (pulmonary) ( 19 ) , CL1-0 (pulmonary) ( 36 ) , CL1-1 (pulmonary) ( 36 ) , CL1-2 (pulmonary) ( 36 ) , CL1-5 (pulmonary) ( 36 ) , CMK (megakaryoblast) ( 17 ) , COS (fibroblast) ( 58 ) , CTS (myeloid) ( 17 ) , DG75 (B lymphocyte) ( 37 ) , DOHH2 ('B lymphocyte, precursor') ( 17 ) , endothelial-aorta ( 21 ) , fibroblast-skin ( 60 ) , FL-18 (B lymphocyte) ( 8 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 22 ) , Flp-In T-Rex-293 (epithelial) ( 22 ) , H2009 (pulmonary) ( 19 ) , H2077 (pulmonary) ( 19 ) , H2887 (pulmonary) ( 19 ) , H322M (pulmonary) ( 19 ) , HCC1359 (pulmonary) ( 19 ) , HCC1937 (breast cell) ( 19 ) , HCC2279 (pulmonary) ( 19 ) , HCC366 (pulmonary) ( 19 ) , HCC4006 (pulmonary) ( 19 ) , HCC78 (pulmonary) ( 19 ) , HCC827 (pulmonary) ( 19 ) , HCT116 (intestinal) ( 47 , 48 ) , HEL (erythroid) ( 17 , 20 ) , HeLa (cervical) ( 16 , 29 , 33 , 44 , 48 , 49 , 51 , 54 , 55 , 56 , 59 , 62 ) , HeLa S3 (cervical) ( 43 ) , hepatocyte-liver ( 40 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 7 ) , HMLER ('stem, breast cancer') ( 7 ) , HOP62 (pulmonary) ( 19 ) , HUES-7 ('stem, embryonic') ( 45 ) , HUES-9 ('stem, embryonic') ( 32 ) , JEKO-1 (B lymphocyte) ( 8 ) , Jurkat (T lymphocyte) ( 14 , 24 , 25 , 35 , 50 , 57 , 61 ) , K562 (erythroid) ( 16 , 44 , 53 ) , Kasumi-1 (myeloid) ( 17 ) , KG-1 (myeloid) ( 17 , 26 ) , Kit225 (T lymphocyte) ( 28 ) , LCLC-103H (pulmonary) ( 19 ) , leukocyte-blood ( 41 ) , liver ( 10 ) , LNCaP (prostate cell) ( 42 ) , LOU-NH91 (squamous) ( 19 ) , lung ( 12 ) , MCF-7 (breast cell) ( 19 ) , MDA-MB-231 (breast cell) ( 19 ) , MDA-MB-468 (breast cell) ( 19 ) , MV4-11 (macrophage) ( 17 ) , NCEB-1 (B lymphocyte) ( 8 ) , NCI-H1395 (pulmonary) ( 19 ) , NCI-H1568 (pulmonary) ( 19 ) , NCI-H157 (pulmonary) ( 19 ) , NCI-H1648 (pulmonary) ( 19 ) , NCI-H1666 (pulmonary) ( 19 ) , NCI-H2030 (pulmonary) ( 19 ) , NCI-H2172 (pulmonary) ( 19 ) , NCI-H322 (pulmonary) ( 19 ) , NCI-H460 (pulmonary) ( 19 , 48 ) , NCI-H520 (squamous) ( 19 ) , NCI-H647 (pulmonary) ( 19 ) , OCI-ly1 (B lymphocyte) ( 8 ) , OPM-2 (plasma cell) ( 17 ) , P31/FUJ (erythroid) ( 17 ) , PC9 (pulmonary) ( 6 , 19 ) , RAMOS (B lymphocyte) ( 8 ) , REC-1 (B lymphocyte) ( 8 ) , RL ('B lymphocyte, precursor') ( 17 ) , RPMI-8266 (plasma cell) ( 17 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 9 ) , SKBr3 (breast cell) ( 18 ) , SU-DHL-4 (B lymphocyte) ( 8 ) , SU-DHL-6 (B lymphocyte) ( 17 ) , TERT20 ('stem, mesenchymal') ( 52 ) , U-1810 (pulmonary) ( 31 ) , U266 (plasma cell) ( 17 ) , UPN-1 (B lymphocyte) ( 8 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Putative in vivo kinases:	PKCT (human) ( 5 )
Kinases, in vitro:	PKCT (human) ( 5 )
Treatments:	EGF ( 56 ) , IL-2 ( 28 ) , metastatic potential ( 36 )

Downstream Regulation
Effects of modification on ARHGEF6:	activity, induced ( 5 )
Effects of modification on biological processes:	cell growth, induced ( 5 ) , cell motility, induced ( 5 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
4	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
5	Llavero F, et al. (2015) Guanine nucleotide exchange factor αPIX leads to activation of the Rac 1 GTPase/glycogen phosphorylase pathway in interleukin (IL)-2-stimulated T cells. J Biol Chem 290, 9171-82 25694429 Curated Info
6	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
7	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
8	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
9	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
10	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
11	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
12	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
13	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
14	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
15	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
16	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
17	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
18	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
19	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
20	Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66 22547687 Curated Info
21	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
22	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
23	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
24	Guo A (2012) CST Curation Set: 13865; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
25	Mulhern D (2012) CST Curation Set: 13758; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
26	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
27	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
28	Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91 21722762 Curated Info
29	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
30	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
31	Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78 21413766 Curated Info
32	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
33	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
34	Herskowitz JH, et al. (2010) Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration. J Proteome Res 9, 6368-79 20886841 Curated Info
35	Possemato A (2010) CST Curation Set: 10868; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
36	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
37	Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72 20562096 Curated Info
38	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
39	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
40	Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9 20166139 Curated Info
41	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
42	Chen L, Giorgianni F, Beranova-Giorgianni S (2010) Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry. J Proteome Res 9, 174-8 20044836 Curated Info
43	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
44	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
45	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
46	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
47	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info
48	Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74 19415658 Curated Info
49	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
50	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
51	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
52	Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313 18578522 Curated Info
53	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
54	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
55	McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80 18212344 Curated Info
56	Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51 18220336 Curated Info
57	Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
58	Wang Y, et al. (2007) Profiling signaling polarity in chemotactic cells. Proc Natl Acad Sci U S A 104, 8328-33 17494752 Curated Info
59	Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92 16964243 Curated Info
60	Yang F, et al. (2006) Phosphoproteome profiling of human skin fibroblast cells in response to low- and high-dose irradiation. J Proteome Res 5, 1252-60 16674116 Curated Info
61	Zheng H, Hu P, Quinn DF, Wang YK (2005) Phosphotyrosine proteomic study of interferon alpha signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. Mol Cell Proteomics 4, 721-30 15659558 Curated Info
62	Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5 15302935 Curated Info